A randomized study of misonidazole and radiotherapy for grade 3 and 4 cerebral astrocytoma | Zendy

N M Bleehen | Zendy; Chris Wiltshire | Zendy; P N Plowman | Zendy; Janet Watson | Zendy; J. R. W. Gleave | Zendy; Ann Holmes | Zendy; W S Lewin | Zendy; C. S. Treip | Zendy; Tanya Hawkins | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A randomized study of misonidazole and radiotherapy for grade 3 and 4 cerebral astrocytoma

Author(s) -

N M Bleehen,

Chris Wiltshire,

P N Plowman,

Janet Watson,

J. R. W. Gleave,

Ann Holmes,

W S Lewin,

C. S. Treip,

Tanya Hawkins

Publication year - 1981

Publication title -

british journal of cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.833

H-Index - 236

eISSN - 1532-1827

pISSN - 0007-0920

DOI - 10.1038/bjc.1981.64

Subject(s) - misonidazole , medicine , astrocytoma , radiosensitizer , radiation therapy , nuclear medicine , oncology , radiation dose , randomized controlled trial , glioma , cancer research , biology , biochemistry , in vitro

The results are reported of a small clinical trial carried out to assess the potential value of the hypoxic cell radiosensitizer misonidazole in the radiation treatment of Grade 3 and 4 supratentorial astrocytomas. A total of 55 patients were randomly allocated to one of 3 treatment groups. No significant differences were seen between the median survivals of patients in the 2 control radiation groups and that of the third group in which oral misonidazole at a dose of 3 g/m2 preceded each of 4 weekly radiation doses. Possible reasons why no improvement was seen are discussed in detail.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research